A shift in how IoT is secured by default

Tern plc

The release of KeyScaler 2025 marks a transformational moment for organisations wrestling with sprawling IoT and OT device estates. Rather than accepting the traditional burden of manual certificate issuance, policy definition and certificate revocation across thousands or even millions of devices, KeyScaler 2025 introduces a fully automated, AI‑driven trust lifecycle.

Manual processes have long been the Achilles’ heel of large‑scale deployments, introducing delays, human error and security gaps. By embedding AI that continuously monitors device behaviour, identity attributes and compliance posture, KeyScaler 2025 is designed to detect anomalies and potential threats in real time, and to trigger remediation automatically.

The platform incorporates a ‘Policy Intelligence Engine’ that enforces zero‑trust principles dynamically, adapts permissions based on contextual threat data and ensures data exchanges remain encrypted and auditable. For industries such as manufacturing, healthcare, energy or logistics, these features offer critical assurances.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search